Amelioration of hypoglycemia with octreotide therapy in metastatic insulinoma with positive octreotide scan

Pancreas

Volumn 40, Issue 1, 2011, Pages 173-175

  Wade, Alisha N ^a   Cheng, Gang ^a   Teitelbaum, Ursina ^a   Patel, Aalpen A ^a   Alavi, Abass ^a   Rickels, Michael R ^a  

^a HOSPITAL OF THE UNIVERSITY OF PENNSYLVANIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCOSE; OCTREOTIDE; PENTETREOTIDE IN 111;

ADULT; CASE REPORT; CLINICAL FEATURE; COMPUTER ASSISTED TOMOGRAPHY; CONTINUOUS INFUSION; DISEASE COURSE; HUMAN; HYPOGLYCEMIA; INSULINOMA; LETTER; MALE; METASTASIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PRIORITY JOURNAL; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

HUMANS; HYPOGLYCEMIA; INSULINOMA; MALE; MIDDLE AGED; NEOPLASM METASTASIS; OCTREOTIDE; PANCREATIC NEOPLASMS; TOMOGRAPHY, EMISSION-COMPUTED, SINGLE-PHOTON;

EID: 78650958451     PISSN: 08853177     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPA.0b013e3181fa46f2     Document Type: Letter

References (10)

1. Lamberts SWJ, Krenning EP, Reubi JC. The role of somatostatin and its analogs in the diagnosis and treatment of tumors. Endocr Rev. 1991;12:450-482.
2. Bertherat J, Tenenbaum F, Perlemoine K, et al. Somatostatin receptors 2 and 5 are the major somatostatin receptors in insulinomas: an in vivo and in vitro study. J Clin Endocrinol Metab. 2003;88: 5353-5360.
3. Healy ML, Dawson SJ, Murray RML, et al. Severe hypoglycaemia after long-acting octreotide in a patient with an unrecognized malignant insulinoma. Intern Med J. 2007;37:406-409.
4. Stehouwer CDA, Lems WF, Fischer HRA, et al. Aggravation of hypoglycemia in insulinoma patients by the long-acting somatostatin analog octreotide (sandostatin). Acta Endocrinologica. 1989;121:34-40.
5. Schillaci O, Massa R, Scopinaro F. In-111-pentetreotide scintigraphy in the detection of insulinomas: importance of SPECT imaging. J Nucl Med. 2000;41: 459-462.
6. Oberg K, Kvols L, Caplin M, et al. Consensus report on the use of somatostatin analogs for the management of neuroendocrine tumors of the gastroenteropancreatic system. Ann Oncol. 2004;15:966-973.
7. Goode PN, Farndon JR, Anderson J, et al. Diazoxide in the management of patients with insulinoma. World J Surg. 1986;10: 586-592.
8. Altszuler N, Hampshire J, Moraru E. Mechanism of diazoxide-induced hyperglycemia. Diabetes. 1977;26: 931-935.
9. Bourcier ME, Sherrod A, DiGuardo M, et al. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab. 2009;94:3157-3162.
10. Romeo S, Milione M, Gatti A, et al. Complete clinical remission and disappearance of liver metastases after treatment with somatostatin analogue in a 40-year-old woman with a malignant insulinoma positive for somatostatin receptors type 2. Horm Res. 2006;65: 120-125.